Published in Hepatitis Weekly, May 4th, 1998
However, the trial - the largest reported to date comparing the short-term and long-term efficacy of lymphoblastoid interferon with recombinant interferon alpha (IFN-(alpha)) - reported an overall sustained alanine aminotransferase (ALT) response of just 10 percent of all treated patients.
"The reasons for the relatively disappointing results in the present trials were not apparent from a consideration of the pretreatment demographic and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.